Investment of the pharmaceutical company Biopharma is $15-20 million, co-owner of the company Kostiantyn Yefymenko has said.
“We have already invested $125 million in production facilities. We continue to invest $15-20 million every year. And we have not yet begun to build a second plant, for example, in Egypt. When we build it, investments will be even bigger,” he said during a discussion panel at the Kyiv International Economic Forum.
Yefymenko said that “the decision to sell the plant to the pharmaceutical company STADA was strategic.”
“We have built two plants. One plant that produces generic drugs, hormones and probiotics, we brought to a turnover of EUR 40 million and sold it completely to STADA,” he said, adding that “STADA and not only STADA is watching and continues to look at not only Biopharma, but also other pharmaceutical companies.”
Yefymenko spoke about the negotiations between Biopharma and STADA. “I can’t say that it took much time for them to come. STADA bought the plant and we have a completely transparent fence with them, because we are on the same site. STADA and I have remained partners, since all the infrastructure that we built, we have with them 50×50. This is a transformer substation, gas hydraulic fracturing, water supply, sewage and fire protection system,” he said.
“STADA is considering the possibility of expanding its plant, we are considering expanding our plant,” Yefymenko said
